Management

Michael Nelson

Michael Nelson, JD
Chief Executive Officer


Mr. Nelson graduated from Cornell University and received his J.D. from New York University School of Law. He has a background in law, finance and management. Previously, he was an analyst at Barclays Capital and ING, was an investment banker at Westwood Capital and CIBC World Markets and practiced law at Willkie Farr & Gallagher and Dewey Ballantine.

Erick Berglund

Erick Berglund, PhD
Chief Scientific Officer


Dr. Berglund received his BS and MS from the University of N.H. and Boston University School of Medicine, respectively, then received his PhD in biochemistry from Goethe University in Frankfurt, Germany. He initially worked as a researcher at Sanofi‐Aventis, then became a USPTO registered patent agent, going on to work in business development and strategy at Kyorin Pharmaceuticals, and then as CEO of Vaxiva KK, a Tokyo-based vaccine company. Prior to launching Intrommune, Dr. Berglund was a Medical Strategy Director at H4B Chelsea, a global healthcare communications consultancy in NYC.

Michelle Mantia
Operations Manager


Ms. Mantia earned her B.A. in Actuarial Science from Baruch College and has over 6 years experience working with both corporate and arts non-profit organizations. Having studied saxophone for many years and coming from a music background, Michelle enjoys sharing her time spent working with both growing arts organizations and innovative biotechnologies. She currently serves on the MICHIYAYA Dance Company’s Board of Directors.

Alain Van Loo

Alain Van Loo
Chief Operating Officer


Mr. Van Loo graduated from Lafayette College with a dual degree in International Affairs and Government/Law, with a minor in German.  Alain’s professional background entails building and managing teams in institutional trading, investment banking and private capital investment.  He was a Director at Deutsche Bank in both New York and London as well as Portfolio Manager and Strategist for the global macro hedge fund, Blenheim Capital Management.  He was also Chief Investment Officer and spearheaded the growth strategy for the Sharp Financial Group before becoming COO at Intrommune.

 

Keith James, CPA, MBA, CGMA
Chief Financial Officer


Mr. James graduated from Strayer University with a BS in Accounting and holds an MBA in Operational Management from the University of Scranton and is a licensed Certified Public Accountant in the State of Delaware. He has worked in life science companies of all sizes and has led major departments and initiatives to include finance, FP&A, HR, IT, process improvement, due diligence and operational integration for over 20 years. He has worked in start-ups, privately backed companies, pre-IPO, and publicly traded companies as Principal Accounting Officer. He has been instrumental in various capital raises in both debt and equity transactions.

 

Abhit Singh, MD
VP of Medical Affairs


Dr. Singh received his MD from Government Medical College, India, and an MHA in Healthcare from the University of Southern California, Los Angeles. Besides previous experience as a practicing Primary Care Physician, Dr. Singh served as the Chief Medical Officer for Los Angeles based Clear Protocol, Inc., an Augmented Reality Google- Glass Medical Technology Startup deploying CMS mandated checklists in Medicine and Surgery. With close to two decades of professional experience in Healthcare and Biotechnology, Dr. Singh’s current roles include Chief Medical Advisor for WeHeal Foundation, Medical Advisory Board Member for Exosomics Inc and PrognosDx Health, and Senior Corporate Ambassador for Relamatrix Group Inc. Throughout his career, Dr. Singh has received numerous accolades including ‘Top Medical Advisor of 2019′ by the International Association of Top Professionals, NYC, and has been declared one of the ‘Top 100 Leaders in Healthcare’ by the International Forum for Advancements in Healthcare, IFAH.

Michael Nelson

Michael Nelson, JD
Chief Executive Officer


Mr. Nelson graduated from Cornell University and received his J.D. from New York University School of Law. He has a background in law, finance and management. Previously, he was an analyst at Barclays Capital and ING, was an investment banker at Westwood Capital and CIBC World Markets and practiced law at Willkie Farr & Gallagher and Dewey Ballantine.

Erick Berglund

Erick Berglund, PhD
Chief Scientific Officer


Dr. Berglund received his BS and MS from the University of N.H. and Boston University School of Medicine, respectively, then received his PhD in biochemistry from Goethe University in Frankfurt, Germany. He initially worked as a researcher at Sanofi‐Aventis, then became a USPTO registered patent agent, going on to work in business development and strategy at Kyorin Pharmaceuticals, and then as CEO of Vaxiva KK, a Tokyo-based vaccine company. Prior to launching Intrommune, Dr. Berglund was a Medical Strategy Director at H4B Chelsea, a global healthcare communications consultancy in NYC.

Michelle Mantia
Operations Manager


Ms. Mantia earned her B.A. in Actuarial Science from Baruch College and has over 6 years experience working with both corporate and arts non-profit organizations. Having studied saxophone for many years and coming from a music background, Michelle enjoys sharing her time spent working with both growing arts organizations and innovative biotechnologies. She currently serves on the MICHIYAYA Dance Company’s Board of Directors.

Alain Van Loo

Alain Van Loo
Chief Operating Officer


Mr. Van Loo graduated from Lafayette College with a dual degree in International Affairs and Government/Law, with a minor in German.  Alain’s professional background entails building and managing teams in institutional trading, investment banking and private capital investment.  He was a Director at Deutsche Bank in both New York and London as well as Portfolio Manager and Strategist for the global macro hedge fund, Blenheim Capital Management.  He was also Chief Investment Officer and spearheaded the growth strategy for the Sharp Financial Group before becoming COO at Intrommune.

 

Keith James, CPA, MBA, CGMA
Chief Financial Officer


Mr. James graduated from Strayer University with a BS in Accounting and holds an MBA in Operational Management from the University of Scranton and is a licensed Certified Public Accountant in the State of Delaware. He has worked in life science companies of all sizes and has led major departments and initiatives to include finance, FP&A, HR, IT, process improvement, due diligence and operational integration for over 20 years. He has worked in start-ups, privately backed companies, pre-IPO, and publicly traded companies as Principal Accounting Officer. He has been instrumental in various capital raises in both debt and equity transactions.

 

Abhit Singh, MD
VP of Medical Affairs


Dr. Singh received his MD from Government Medical College, India, and an MHA in Healthcare from the University of Southern California, Los Angeles. Besides previous experience as a practicing Primary Care Physician, Dr. Singh served as the Chief Medical Officer for Los Angeles based Clear Protocol, Inc., an Augmented Reality Google- Glass Medical Technology Startup deploying CMS mandated checklists in Medicine and Surgery. With close to two decades of professional experience in Healthcare and Biotechnology, Dr. Singh’s current roles include Chief Medical Advisor for WeHeal Foundation, Medical Advisory Board Member for Exosomics Inc and PrognosDx Health, and Senior Corporate Ambassador for Relamatrix Group Inc. Throughout his career, Dr. Singh has received numerous accolades including ‘Top Medical Advisor of 2019′ by the International Association of Top Professionals, NYC, and has been declared one of the ‘Top 100 Leaders in Healthcare’ by the International Forum for Advancements in Healthcare, IFAH.

SCIENTIFIC ADVISORY BOARD

Greg Plunkett, PhD
CMC Advisor


Greg Plunkett is an independent consultant providing support for the allergy immunotherapy field. He has over 40 years of experience with allergen manufacturing, quality control and pharma regulations with 18 publications and over 68 abstracts. He most recently was the Director of the Allergy Research Lab for ALK USA allergen extract manufacturing since 2001. His focus was on the characterization of allergen source material and finished products. Prior to joining ALK, Dr. Plunkett served as a Research Scientist in the laboratories of Hollister-Stier where in addition to allergen characterization, he developed in vitro tests for diagnosing allergy. Dr. Plunkett sits on allergy immunotherapy committees for national allergy societies, is the Science officer for the US Allergen Manufacturers Association and has twice been a member of the FDA Allergenics Products Advisory Committee.  Dr. Plunkett has a bachelor’s degree in Chemistry from Cal State University, Fullerton and a Ph.D. in biochemistry from Washington State University.

 

William Reisacher, MD
Inventor of OMIT; Senior Scientific Advisor


Dr. Reisacher is a General Otolaryngologist and Otolaryngic Allergist on the full-time Faculty of Weill Cornell Medical College, where he is Associate Professor of Otolaryngology and the Director of Allergy Services within the Department of Otolaryngology-Head and Neck Surgery. He has served on the Board of Directors of the AAOA and the Board of Governors of the American Academy of Otolaryngology – Head and Neck Surgery, and he lectures both nationally and internationally.

Anthony Robinson, CRNP, MBA
Clinical Advisor


Anthony Robinson is a drug development executive with over 25 years experience in biopharmaceutical, medical device and healthcare industries. He has led, advised and managed clinical development, regulatory affairs and pharmaceutical development teams for virtual startups with one product to mid-cap pharmaceutical companies with larger pipelines in global markets. Anthony has contributed to over 10 products approved (small and large molecules) by US and global regulatory authorities, and over 20 additional INDs/CTAs/New Regulated Clinical Trial Programs.

 

BUSINESS ADVISORY BOARD

Tonya Winders, MBA
Stakeholder Outreach Advisor


Tonya Winders, MBA is currently the President and Chief Executive Officer of Allergy & Asthma Network, the leading patient advocacy organization dedicated to ending the needless death and suffering due to asthma, allergies and related conditions.

Tonya has over 17 years experience in leadership roles within the allergy and asthma industry. From sales and marketing leadership to managed markets access, she has worked tirelessly to ensure patients have access to effective diagnostic and treatment tools.

Greg Van Gasse, MBA
Marketing Advisor


Greg has over 30 years of global consumer brand experience that includes over a decade as CEO/President/Board/Founder/Chairman. His experience ranges from Fortune 500 companies to start ups. Greg consistently finds and executes strategic paths to successful company and brand performance. He has won numerous major awards for his ability to create, grow, and turnaround companies in fast pace industries that include footwear/apparel, cosmetics, personal care, and household products. Industry awards include: Fragrance of The Year, Footwear Brand of the Year, and Finalist NW Startup of the Year.

As a talented and seasoned senior executive with Colgate-Palmolive and Unilever he was responsible for successfully building and turning around billion dollar global brands such as Colgate Dental Care, Palmolive Brands, Vaseline and Ponds Skin Care. As a CEO/President and Board Member for leading footwear companies Greg brought his expertise to build wholesale and retail teams to grow leading brands such as Dr. Marten’s, Florsheim, and Naturalizer. His start-up experience includes creating a footwear company to save women’s feet from the damage caused by high heels, Oh! Shoes, Inc. Greg is currently focused on teaming with early stage companies that have measurable social and/or environmental impact with the potential to grow into global mega brands.

Jotin Marango, MD, PHD
Corporate Development & Investment Advisor


Dr. Marango is the Chief Business Officer and Senior Vice President at Aptose Biosciences, a clinical stage company developing precision therapies in hematology and oncology. Prior to joining Aptose, Dr. Jotin Marango was a managing director and senior research analyst at Roth Capital Partners covering oncology with a focus on epigenetic and molecularly targeted therapies, as well as pulmonary medicine and allergy therapeutics. Dr. Marango began his career in equity research with Collins Stewart/Canaccord Genuity. Previously, Dr. Marango also served as Chief Operating Officer at the Samuel Waxman Cancer Research Foundation, where he oversaw academic collaborations in translational therapeutics, as well as venture philanthropy initiatives in drug development. Dr. Marango studied chemistry and classical literature at Harvard University and later received his Doctor of Medicine and Doctor of Philosophy degrees from the Mount Sinai School of Medicine of New York University.

 

Jack Levitt, MBA
Executive Development Advisor


Jack began his career in banking as a commercial lender, where he developed and ran a formal credit training program for new analysts to become lenders. After earning his MBA from Rutgers Graduate School of Management, he moved to the corporate world and led teams in both Finance/Accounting and Sales/Marketing for a Bell Atlantic subsidiary. Jack was later recruited by Lucent Technologies to join their Marketing and Offer management team as a coach and trainer. Subsequently, Jack earned an Executive Masters in Technology Management from Stevens Institute of Technology and collaborated with Stevens to launch PlasmaSol, a company that commercializes a non-thermal plasma technology. PlasmaSol was recognized as the Environmental Company of the Year for the State of NJ and was eventually sold to Stryker Medical. Jack is also a certified Executive Coach specializing in Individual Leadership Coaching and High Performance Team Development, as well as Executive Presentation Coaching.

 

WE WANT TO THANK THE FOLLOWING FOR

CLINICAL GUIDANCE

David Fleischer, MD


Dr. David Fleischer is Associate Professor of Pediatrics at the University of Colorado School of Medicine, Director of the Food Challenge Unit at Colorado Children’s Hospital, and board certified in both Allergy and Immunology and Pediatrics. He has led research sites for numerous multi-center studies, including NIH-NIAID funded CoFAR studies on peanut sublingual immunotherapy, egg oral immunotherapy, and the causes and progression of peanut allergies.

Matthew Greenhawt, MD


Dr. Matthew Greenhawt is Assistant Professor of Pediatrics at the University of Colorado School of Medicine. He brings expertise in health services research, healthcare policy, and biostatistics. He has published over 50 articles on topics including the impact of food allergies on quality of life, vaccine safety, and food allergy healthcare policy, in addition to funded research into phenotypes in eosinophilic esophagitis and cost-effectiveness analysis.

Wesley Burks, MD


Dr. A. Wesley Burks is CEO of the University of North Carolina at Chapel Hill School of Medicine, the Curnen Distinguished Professor of Pediatrics, and Executive Director of the UNC Food Allergy Initiative. Dr. Burks joins the Intrommune Advisory Board with 30 years’ experience conducting and leading clinical research on clinical presentations of food allergy, the properties of foods contributing to allergenicity, and food allergy immunotherapy, including pioneering research on sublingual immunotherapy for peanut allergy.